Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ophthalmology

Free Subscription Articles published in Lancet Retrieve available abstracts of 45 articles: HTML format

Single Articles

November 2024
1. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
   Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
   Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
   PubMed     Abstract available
   
   
   
2. HIRAMI Y, Mandai M
   Opening the door to widespread iPSC-derived regenerative therapy for corneal epithelial opacity.
   Lancet. 2024 Nov 7:S0140-6736(24)01965-2. doi: 10.1016/S0140-6736(24)01965.
   PubMed    
   
   
   September 2024
3. YANG P, Pardon LP, Ho AC, Lauer AK, et al
   Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
   Lancet. 2024;404:962-970.
   PubMed     Abstract available
   
   
   
4. MACLAREN RE
   Gene therapy in the early stages of retinal degeneration.
   Lancet. 2024;404:911-913.
   PubMed    
   
   
   August 2024
5. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
   Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
   Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
   PubMed     Abstract available
   
   
   
6. MAMAS MA, Mintz GS
   Optical coherence tomography imaging for complex percutaneous coronary intervention.
   Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
   PubMed    
   
   
   
7. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
   Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
   Lancet. 2024;404:540-553.
   PubMed     Abstract available
   
   
   
8. COLAFRANCESCO S, Priori R
   Sjogren's disease: a new era for clinical trials?
   Lancet. 2024;404:498-499.
   PubMed    
   
   
   July 2024
9. PATEL JN, Miller NR
   Non-arteritic anterior ischaemic optic neuropathy causes sudden-onset painless loss of vision.
   Lancet. 2024;404:67.
   PubMed    
   
   
   June 2024
10. YING GS, VanderBeek BL
    Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Lancet. 2024 Jun 11:S0140-6736(24)00915-2. doi: 10.1016/S0140-6736(24)00915.
    PubMed    
    
    
    
11. JACKSON TL, Desai R, Wafa HA, Wang Y, et al
    Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
    Lancet. 2024 Jun 11:S0140-6736(24)00687-1. doi: 10.1016/S0140-6736(24)00687.
    PubMed     Abstract available
    
    
    May 2024
12. PROUDLOCK FA, Hisaund M, Maconachie G, Papageorgiou E, et al
    Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
    Lancet. 2024;403:1766-1778.
    PubMed     Abstract available
    
    
    
13. ZHOU S, Zhou J
    New advances in amblyopia therapy: early patching is more effective than extended optical treatment.
    Lancet. 2024;403:1725-1727.
    PubMed    
    
    
    April 2024
14. WILENIUS M, Jernman J, Hietaharju A, Salonen T, et al
    Swollen eyelids caused by polyvinylpyrrolidone histiocytosis with intravenous methylphenidate.
    Lancet. 2024;403:1574-1575.
    PubMed    
    
    
    March 2024
15. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
    Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
    PubMed     Abstract available
    
    
    
16. RAKOCZY EP
    The promise of long-term treatment for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
    PubMed    
    
    
    
17. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available
    
    
    
18. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    PubMed     Abstract available
    
    
    
19. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
    Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
    PubMed     Abstract available
    
    
    
20. CHEW EY
    Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
    PubMed    
    
    
    
21. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    PubMed    
    
    
    January 2024
22. CYPERS G, Tsitsi P
    Retinitis pigmentosa and pes cavus in PHARC-polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract-syndrome in a 62-year-old man.
    Lancet. 2024;403:391.
    PubMed    
    
    
    
23. SPEKREIJSE L, van den Biggelaar F, Nuijts R
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery - Authors' reply.
    Lancet. 2024;403:354.
    PubMed    
    
    
    
24. LIN JC, Greenberg PB
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353.
    PubMed    
    
    
    
25. TING DSJ, Buchan JC
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353-354.
    PubMed    
    
    
    
26. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    PubMed     Abstract available
    
    
    October 2023
27. HEIER JS, Lad EM, Holz FG, Rosenfeld PJ, et al
    Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
    Lancet. 2023;402:1434-1448.
    PubMed     Abstract available
    
    
    
28. CHEW EY
    Complement inhibitors for the treatment of geographic atrophy.
    Lancet. 2023;402:1396-1398.
    PubMed    
    
    
    September 2023
29. JAYARAM H, Kolko M, Friedman DS, Gazzard G, et al
    Glaucoma: now and beyond.
    Lancet. 2023 Sep 21:S0140-6736(23)01289-8. doi: 10.1016/S0140-6736(23)01289.
    PubMed     Abstract available
    
    
    June 2023
30. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    PubMed    
    
    
    May 2023
31. DMUCHOWSKA DA, Obuchowska I, Konopinska J
    Immediate versus delayed sequential bilateral cataract surgery.
    Lancet. 2023 May 15:S0140-6736(23)00692-X. doi: 10.1016/S0140-6736(23)00692.
    PubMed    
    
    
    
32. SPEKREIJSE L, Simons R, Winkens B, van den Biggelaar F, et al
    Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
    Lancet. 2023 May 15:S0140-6736(23)00525-1. doi: 10.1016/S0140-6736(23)00525.
    PubMed     Abstract available
    
    
    
33. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available
    
    
    March 2023
34. GUYMER RH, Campbell TG
    Age-related macular degeneration.
    Lancet. 2023 Mar 27:S0140-6736(22)02609-5. doi: 10.1016/S0140-6736(22)02609.
    PubMed     Abstract available
    
    
    December 2022
35. CICINELLI MV, Buchan JC, Nicholson M, Varadaraj V, et al
    Cataracts.
    Lancet. 2022 Dec 21:S0140-6736(22)01839-6. doi: 10.1016/S0140-6736(22)01839.
    PubMed     Abstract available
    
    
    September 2022
36. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.
    PubMed    
    
    
    
37. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.
    PubMed    
    
    
    August 2022
38. BAGENAL J, Khanna R, Hawkes S
    Not misogynistic but myopic: the new women's health strategy in England.
    Lancet. 2022 Aug 10. pii: S0140-6736(22)01486.
    PubMed    
    
    
    January 2022
39. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    PubMed     Abstract available
    
    
    
40. HEIER JS, Khanani AM, Quezada Ruiz C, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00010.
    PubMed     Abstract available
    
    
    
41. CHIA MA, Keane PA
    Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00105.
    PubMed    
    
    
    
42. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    PubMed    
    
    
    
43. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available
    
    
    
44. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    PubMed    
    
    
    October 2021
45. AYADI K, Gallaoui S, Ben Nsir A
    Pituitary apoplexy, but not as we thought: a xanthogranuloma rather than an adenoma.
    Lancet. 2021;398:e16.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.